Skip to contentV
VitaNova Life Sciences Corp
V
VNOVVitaNova Life Sciences Corp Q2 2026 · 10-Q
Revenue$427.12K$427.12K+46.2% vs Q2 2025 Net Income$35.81K$35.81K+9.7% vs Q2 2025 EPS Diluted$0.00$0.00— vs Q2 2025 Gross Profit$260,803+67.4% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
VitaNova Life Sciences Corp · CIK 1699709 · Engraved from SEC EDGAR
Operating Cash Flowderived$212,660+2,327.6% Margins · derivedGross margin61.1%+7.7 pt vs Q2 2025
Operating margin23.2%+1.8 pt vs Q2 2025
Net margin8.4%−2.8 pt vs Q2 2025
ended Oct 31, 2025 · filed Dec 15, 2025 · 45 d after period end